Deep immunoglobulin repertoire sequencing depicts a comprehensive atlas of spike-specific antibody lineages shared among COVID-19 convalescents

References

• Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020 May;581(7807):215–220. doi:10.1038/s41586-020-2180-5. PubMed PMID: 32225176.
   PubMed Web of Science ®Google Scholar
• Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021 Feb;21(2):73–82. doi:10.1038/s41577-020-00480-0. PubMed PMID: 33340022; PubMed Central PMCID: PMCPMC7747004.
   PubMed Web of Science ®Google Scholar
• Cerutti G, Guo Y, Zhou T, et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe. 2021 May 12;29(5):819–833 e7. doi:10.1016/j.chom.2021.03.005. PubMed PMID: 33789084; PubMed Central PMCID: PMCPMC7953435.
   PubMed Web of Science ®Google Scholar
• Li D, Edwards RJ, Manne K, et al. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell. 2021 Aug 5;184(16):4203–4219 e32. doi:10.1016/j.cell.2021.06.021. PubMed PMID: 34242577; PubMed Central PMCID: PMCPMC8232969.
   PubMed Web of Science ®Google Scholar
• Cromer D, Steain M, Reynaldi A, et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe. 2022;3(1):e52–e61. doi:10.1016/s2666-5247(21)00267-6
   PubMedGoogle Scholar
• Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021 Jul;27(7):1205–1211. doi:10.1038/s41591-021-01377-8. PubMed PMID: 34002089.
   PubMed Web of Science ®Google Scholar
• Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608(7923):593–602. doi:10.1038/s41586-022-04980-y
   PubMed Web of Science ®Google Scholar
• Deng X, Garcia-Knight MA, Khalid MM, et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell. 2021 Jun 24;184(13):3426–3437 e8. doi:10.1016/j.cell.2021.04.025. PubMed PMID: 33991487; PubMed Central PMCID: PMCPMC8057738.
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Jumnainsong A, Onsirisakul N, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010;328:745–747. doi:10.1126/science.1185181
   PubMed Web of Science ®Google Scholar
• Cao Y, Jian F, Wang J, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent omicron RBD evolution. Nature. 2022. doi:10.1038/s41586-022-05644-7
   Web of Science ®Google Scholar
• Gruell H, Vanshylla K, Weber T, et al. Antibody-mediated neutralization of SARS-CoV-2. Immunity. 2022 Jun 14;55(6):925–944. doi:10.1016/j.immuni.2022.05.005. PubMed PMID: 35623355; PubMed Central PMCID: PMCPMC9118976.
   PubMed Web of Science ®Google Scholar
• Roltgen K, Boyd SD. Antibody and B cell responses to SARS-CoV-2 infection and vaccination. Cell Host Microbe. 2021 Jul 14;29(7):1063–1075. doi:10.1016/j.chom.2021.06.009. PubMed PMID: 34174992; PubMed Central PMCID: PMCPMC8233571 on topics unrelated to this manuscript, and owns stock in AbCellera Biologics.
   PubMed Web of Science ®Google Scholar
• Elko EA, Nelson GA, Mead HL, et al. COVID-19 vaccination elicits an evolving, cross-reactive antibody response to epitopes conserved with endemic coronavirus spike proteins. Cell Rep. 2022 Jul 5;40(1):111022. doi:10.1016/j.celrep.2022.111022. PubMed PMID: 35753310; PubMed Central PMCID: PMCPMC9188999.
   PubMed Web of Science ®Google Scholar
• Ladner JT, Henson SN, Boyle AS, et al. Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. Cell Rep Med. 2021 Jan 19;2(1):100189. doi:10.1016/j.xcrm.2020.100189. PubMed PMID: 33495758; PubMed Central PMCID: PMCPMC7816965.
   PubMedGoogle Scholar
• Shrock E, Fujimura E, Kula T, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science. 2020 Nov 27;370(6520). doi:10.1126/science.abd4250. PubMed PMID: 32994364; PubMed Central PMCID: PMCPMC7857405.
   PubMed Web of Science ®Google Scholar
• Paschold L, Simnica D, Willscher E, et al. SARS-CoV-2 specific antibody rearrangements in pre-pandemic immune repertoires of risk cohorts and COVID-19 patients. J Clin Invest. 2020 Oct 16. doi:10.1172/JCI142966. PubMed PMID: 33064671.
   Web of Science ®Google Scholar
• Zhang Y, Yan Q, Luo K, et al. Analysis of B cell receptor repertoires reveals key signatures of the systemic B cell response after SARS-CoV-2 infection. J Virol. 2022;96(4):1–23.
   Web of Science ®Google Scholar
• Zhou Y, Zhang J, Wang D, et al. Profiling of the immune repertoire in COVID-19 patients with mild, severe, convalescent, or retesting-positive status. J Autoimmun. 2021 Mar;118:102596. doi:10.1016/j.jaut.2021.102596. PubMed PMID: 33540371; PubMed Central PMCID: PMCPMC7837046.
   PubMed Web of Science ®Google Scholar
• Yan Q, He P, Huang X, et al. Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients. Emerg Microbes Infect. 2021 Dec;10(1):1097–1111. doi:10.1080/22221751.2021.1925594. PubMed PMID: 33944697; PubMed Central PMCID: PMCPMC8183521.
   PubMed Web of Science ®Google Scholar
• Niu X, Li S, Li P, et al. Longitudinal analysis of T and B cell receptor repertoire transcripts reveal dynamic immune response in COVID-19 patients. Front Immunol. 2020;11:582010. doi:10.3389/fimmu.2020.582010. PubMed PMID: 33117392; PubMed Central PMCID: PMCPMC7561365.
   PubMed Web of Science ®Google Scholar
• Song C, Pan W, Brown B, et al. Immune repertoire analysis of normal Chinese donors at different ages. Cell Prolif. 2022;55(11). doi:10.1111/cpr.13311
   Web of Science ®Google Scholar
• Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for illumina sequence data. Bioinformatics. 2014 Aug 1;30(15):2114–2120. doi:10.1093/bioinformatics/btu170. PubMed PMID: 24695404; PubMed Central PMCID: PMCPMC4103590.
   PubMed Web of Science ®Google Scholar
• Magoc T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics. 2011 Nov 1;27(21):2957–2963. doi:10.1093/bioinformatics/btr507. PubMed PMID: 21903629; PubMed Central PMCID: PMCPMC3198573.
   PubMed Web of Science ®Google Scholar
• Bolotin DA, Poslavsky S, Mitrophanov I, et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods. 2015 May;12(5):380–381. doi:10.1038/nmeth.3364. PubMed PMID: 25924071.
   PubMed Web of Science ®Google Scholar
• Wang M, Fan Q, Zhou B, et al. A key F27I substitution within HCDR1 facilitates the rapid maturation of P2C-1F11-like neutralizing antibodies in a SARS-CoV-2-infected donor. Cell Rep. 2022 Sep 13;40(11):111335. doi:10.1016/j.celrep.2022.111335. PubMed PMID: 36057256; PubMed Central PMCID: PMCPMC9395280.
   PubMed Web of Science ®Google Scholar
• Cao Y, Su B, Guo X, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell. 2020 Jul 9;182(1):73–84 e16. doi:10.1016/j.cell.2020.05.025. PubMed PMID: 32425270; PubMed Central PMCID: PMCPMC7231725.
   PubMed Web of Science ®Google Scholar
• Tan TJC, Yuan M, Kuzelka K, et al. Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain. Nat Commun. 2021 Jun 21;12(1):3815. doi:10.1038/s41467-021-24123-7. PubMed PMID: 34155209; PubMed Central PMCID: PMCPMC8217500.
   PubMed Web of Science ®Google Scholar
• Liu H, Wu NC, Yuan M, et al. Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity. Immunity. 2020;53(6):1272–1280.e5. doi:10.1016/j.immuni.2020.10.023
   PubMed Web of Science ®Google Scholar
• Tortorici MA, Czudnochowski N, Starr TN, et al. Broad sarbecovirus neutralization by a human monoclonal antibody. Nature. 2021 Sep;597(7874):103–108. doi:10.1038/s41586-021-03817-4. PubMed PMID: 34280951; PubMed Central PMCID: PMCPMC9341430.
   PubMed Web of Science ®Google Scholar
• Jian F, Feng L, Yang S, et al. Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455-456 enhances antibody evasion and ACE2 binding. bioRxiv. 2023. doi:10.1101/2023.08.30.555211
   PubMedGoogle Scholar
• Jiang N, He J, Weinstein JA, et al. Lineage structure of the human antibody repertoire in response to influenza vaccination. Sci Transl Med. 2013 Feb 6;5(171):171ra19. doi:10.1126/scitranslmed.3004794. PubMed PMID: 23390249; PubMed Central PMCID: PMCPMC3699344.
   PubMed Web of Science ®Google Scholar
• Setliff I, McDonnell WJ, Raju N, et al. Multi-donor longitudinal antibody repertoire sequencing reveals the existence of public antibody clonotypes in HIV-1 infection. Cell Host Microbe. 2018 Jun 13;23(6):845–854 e6. doi:10.1016/j.chom.2018.05.001. PubMed PMID: 29861170; PubMed Central PMCID: PMCPMC6002606.
   PubMed Web of Science ®Google Scholar
• Chen EC, Gilchuk P, Zost SJ, et al. Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals. Cell Rep. 2021 Aug 24;36(8):109604. doi:10.1016/j.celrep.2021.109604. PubMed PMID: 34411541; PubMed Central PMCID: PMCPMC8352653.
   PubMed Web of Science ®Google Scholar
• Seydoux E, Homad LJ, MacCamy AJ, et al. Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation. Immunity. 2020 Jul 14;53(1):98–105 e5. doi:10.1016/j.immuni.2020.06.001. PubMed PMID: 32561270; PubMed Central PMCID: PMCPMC7276322.
   PubMed Web of Science ®Google Scholar
• Yan Q, Hou R, Huang X, et al. Shared IGHV1-69-encoded neutralizing antibodies contribute to the emergence of L452R substitution in SARS-CoV-2 variants. Emerg Microbes Infect. 2022 Dec;11(1):2749–2761. doi:10.1080/22221751.2022.2140611. PubMed PMID: 36288106; PubMed Central PMCID: PMCPMC9662066.
   PubMed Web of Science ®Google Scholar
• Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021 Mar;591(7851):639–644. doi:10.1038/s41586-021-03207-w. PubMed PMID: 33461210; PubMed Central PMCID: PMCPMC8221082.
   PubMed Web of Science ®Google Scholar
• Wang Z, Muecksch F, Schaefer-Babajew D, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021 Jul;595(7867):426–431. doi:10.1038/s41586-021-03696-9. PubMed PMID: 34126625; PubMed Central PMCID: PMCPMC8277577.
   PubMed Web of Science ®Google Scholar
• Kaku CI, Bergeron AJ, Ahlm C, et al. Recall of pre-existing cross-reactive B cell memory following Omicron BA.1 breakthrough infection. Sci Immunol. 2022;7(73):eabq3511. doi:10.1126/sciimmunol.abq3511. PMID: 35549299; PMCID: PMC9097882.
   PubMed Web of Science ®Google Scholar
• Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022;185(14):2422–2433.e13. doi:10.1016/j.cell.2022.06.005
   PubMed Web of Science ®Google Scholar
• Tian X, Zhu X, Song W, et al. The prominent role of a CDR1 somatic hypermutation for convergent IGHV3-53/3-66 antibodies in binding to SARS-CoV-2. Emerg Microbes Infect. 2022 Dec;11(1):1186–1190. doi:10.1080/22221751.2022.2063074. PubMed PMID: 35380101; PubMed Central PMCID: PMCPMC9045774.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Ju B, Ge J, et al. Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. Nat Commun. 2021 Jul 9;12(1):4210. doi:10.1038/s41467-021-24514-w. PubMed PMID: 34244522; PubMed Central PMCID: PMCPMC8270942.
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022 Feb 3;185(3):467–484 e15. doi:10.1016/j.cell.2021.12.046. PubMed PMID: 35081335; PubMed Central PMCID: PMCPMC8723827.
   PubMed Web of Science ®Google Scholar
• Yuan M, Liu H, Wu NC, et al. Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. Biochem Biophys Res Commun. 2021 Jan 29;538:192–203. doi:10.1016/j.bbrc.2020.10.012. PubMed PMID: 33069360; PubMed Central PMCID: PMCPMC7547570.
   PubMed Web of Science ®Google Scholar
• Qi H, Liu B, Wang X, et al. The humoral response and antibodies against SARS-CoV-2 infection. Nat Immunol. 2022;23:1008–1020. doi:10.1038/s41590-022-01248-5
   PubMed Web of Science ®Google Scholar
• Piccoli L, Park YJ, Tortorici MA, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020 Nov 12;183(4):1024–1042 e21. doi:10.1016/j.cell.2020.09.037. PubMed PMID: 32991844; PubMed Central PMCID: PMCPMC7494283.
   PubMed Web of Science ®Google Scholar
• He P, Liu B, Gao X, et al. SARS-CoV-2 Delta and Omicron variants evade population antibody response by mutations in a single spike epitope. Nat Microbiol. 2022 Oct;7(10):1635–1649. doi:10.1038/s41564-022-01235-4. PubMed PMID: 36151403; PubMed Central PMCID: PMCPMC9519457.
   PubMed Web of Science ®Google Scholar
• Li W, Chen Y, Prevost J, et al. Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern. Cell Rep. 2022 Jan 11;38(2):110210. doi:10.1016/j.celrep.2021.110210. PubMed PMID: 34971573; PubMed Central PMCID: PMCPMC8673750.
   PubMed Web of Science ®Google Scholar
• Feldman1 J, Bals J, Altomare CG, et al. Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses. Sci Immunol. 2021;6:1–12.
   Web of Science ®Google Scholar
• Claireaux M, Caniels TG, de Gast M, et al. A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike. Nat Commun. 2022;13(1). doi:10.1038/s41467-022-32232-0
   Web of Science ®Google Scholar
• Briney B, Inderbitzin A, Joyce C, et al. Commonality despite exceptional diversity in the baseline human antibody repertoire. Nature. 2019 Feb;566(7744):393–397. doi:10.1038/s41586-019-0879-y. PubMed PMID: 30664748; PubMed Central PMCID: PMCPMC6411386.
   PubMed Web of Science ®Google Scholar
• Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020 Dec;5(12):1598–1607. doi:10.1038/s41564-020-00813-8. PubMed PMID: 33106674; PubMed Central PMCID: PMCPMC7610833.
   PubMed Web of Science ®Google Scholar
• Marot S, Malet I, Leducq V, et al. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nat Commun. 2021 Feb 8;12(1):844. doi:10.1038/s41467-021-21111-9. PubMed PMID: 33558507; PubMed Central PMCID: PMCPMC7870823.
   PubMed Web of Science ®Google Scholar
• Yu H, Liu B, Zhang Y, et al. Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants. Nat Commun. 2023;14(1). doi:10.1038/s41467-023-36761-0
   Web of Science ®Google Scholar
• Goel RR, Painter MM, Lundgreen KA, et al. Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. Cell. 2022 May 26;185(11):1875–1887 e8. doi:10.1016/j.cell.2022.04.009. PubMed PMID: 35523182; PubMed Central PMCID: PMCPMC8989683.
   PubMed Web of Science ®Google Scholar
• Nutalai R, Zhou D, Tuekprakhon A, et al. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell. 2022 Jun 9;185(12):2116–2131 e18. doi:10.1016/j.cell.2022.05.014. PubMed PMID: 35662412; PubMed Central PMCID: PMCPMC9120130.
   PubMed Web of Science ®Google Scholar
• Ju B, Zhang Q, Wang Z, et al. Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants. Nat Immunol. 2023;24(4):690–699. doi:10.1038/s41590-023-01449-6
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang Z, Zhuang X, et al. Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants. Nat Commun. 2023;14(1). doi:10.1038/s41467-023-37926-7
   Web of Science ®Google Scholar
• Guo Y, Zhang G, Yang Q, et al. Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection. Nat Commun. 2023;14(1). doi:10.1038/s41467-023-39267-x
   Web of Science ®Google Scholar
• Reddy ST, Ge X, Miklos AE, et al. Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells. Nat Biotechnol. 2010 Sep;28(9):965–969. doi:10.1038/nbt.1673. PubMed PMID: 20802495.
   PubMed Web of Science ®Google Scholar